Company intelligence / Profile preview
SANUWAVE Health
Suwanee, Georgia, USAsanuwave.com ↗
- Ownership
- Public · SNWV
- Employees
- ~50
- Development stage
- Commercial
01
Overview
SANUWAVE’s lead product dermaPACE® is FDA-cleared for diabetic foot ulcers following successful Phase III trials showing efficacy over standard of care. The UltraMIST® system is also FDA-approved with nationwide CMS reimbursement. Clinical data support improved healing rates in chronic wounds using these noninvasive energy-based therapies.
- Therapeutic areas
- EndocrinologyDermatologyRheumatologyCardiovascularNeurology
- Modalities
- DeviceNon-pharmacological therapyBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Celularity Inc.
04
Financials
- Market cap
- $19.4M
- Total revenue
- $44.1M
- Enterprise value
- $30.7M
Beyond the preview
Go deeper on SANUWAVE Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SANUWAVE Health.